BlueGnome Announces CytoChip Oligo Solution for High-Resolution Copy Number Analysis
Product News Dec 03, 2008
Following the launch of its CytoChip Focus arrays for haematological and constitutional research, BlueGnome announced the release of its first oligo array solution for cytogenetics. The arrays will be produced by Agilent Technologies Inc.
With an overall resolution of up to 35Kb, and a focus on genomic regions known to be associated with constitutional genetic disorders, the CytoChip Oligo array is designed for cytogenetics applications where high resolution is required. The oligos on the arrays have been designed and empirically validated to deliver improved signal to noise with both high and low quality samples.
The arrays will form a part of BlueGnome’s comprehensive solution for cytogenetics, including BAC arrays, consumables packs and confirmatory FISH probes. Users of the platform will have access to BlueGnome’s leading software, BlueFuse Multi, which in a single framework provides a complete sample and experiment management infrastructure, in addition to single-click image analysis, normalization, visualization and reporting.
Critically, BlueFuse Multi allows users to search their own BAC and oligo array data, and also online databases, to determine regions of likely polymorphism in the genome with a minimum of time consuming manual searching of online databases.
Nick Haan, CEO of BlueGnome commented, “CytoChip oligo arrays will form an important and complementary part of BlueGnome’s complete solution for the cytogenetics community. Combined with the BlueFuse Multi software, the CytoChip oligo solution will allow users to investigate samples at ultra-high resolution in a routine environment, while keeping subjective data interpretation to a minimum.”
“Agilent’s oligo microarray technology is engineered to the highest standards to deliver robust and reproducible results,” stated Yvonne Linney, Ph.D., Agilent vice president and general manager, Genomics. “We are pleased to be working with BlueGnome to deliver a new solution to the cytogenetics community.”